This week the FDA granted Breakthrough Therapy status to three development programs and halted two different clinical trials.  Here are the top regulatory news stories to follow this week: Ocular Therapeutix, which had its lead drug rejected by the FDA last summer said that it remains on track to resubmit its application to the FDA[…]